Fruttamed Clinical studies
Hepato-protective effects of Morinda citrifolia against thioacetamide-induced liver fibrosis
Excessive reactive oxygen species (ROS) can result in inflammation and cytokine secretion in the liver, and then activate hepatic stellate cells that cause the accumulation of extracellular matrix proteins, specifically collagen, in liver tissue. Morinda citrifolia has been used for decades as a nutraceutical in humans. In this clinical study, we aimed to examine if Morinda citrifolia can ameliorate ROS-induced liver fibrosis via a thioacetamide (TAA)-induced rat model.
The 50 rats used in this clinical study were split into five groups of 10 rats each for 8 weeks as follows: (1) control group; (2) TAA; (3) TAA+low-dose NJ (2.51 mL NJ/kg); (4) TAA+medium-dose NJ (5.02 mL NJ/kg); and (5) TAA+high-dose NJ (7.52 mL NJ/kg).
Treatment with TAA resulted in lower body weight and serum lipid levels (p<0.05), while liver weight and collagen contents, and serum alanine aminotransferase and aspartate aminotransferase values were increased (p<0.05). The protective effects of Morinda citrifolia extract on TAA treatment resulted from decreasing endoplasmic reticulum stress-related gene expressions (p<0.05), inflammatory cytokines, collagen accumulation, and matrix metallo-proteinase (MMP-2 and MMP-9) activities, as well as up-regulated (p<0.05) tissue inhibitors of metallo-proteinase (TIMP-1 and TIMP-3) in the liver. Morinda citrifolia extract also increased hepatic antioxidant capacities (p<0.05).
Morinda citrifolia extract manifests a protective potential on liver fibrosis via the enhancement of antioxidant capacities, as well as decreasing endoplasmic-reticulum stress and MMP-2/MMP-9 activities.